Prosecution Insights
Browse Companies Examiners Firms Draft Your Response
Office Actions › Argenx BV › 19257976
Last updated: April 24, 2026
Application No. 19/257,976

Untitled Application

Unknown
Filed
1600
Examiner
TAYLOR, LIA ELAN
Art Unit
1641
Tech Center
argenx BV
Assignee
Argenx BV
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
2y 11m
To Grant
92%
With Interview

This examiner grants 64% of cases after interview

— +27.9% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.
Based on 173 resolved cases, 2023–2026

Examiner Intelligence

TAYLOR, LIA ELAN View full profile →
Grants 64% of resolved cases
64%
Career Allow Rate
110 granted / 173 resolved
+3.6% vs TC avg
Strong +28% interview lift
Without
With
+27.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
48 currently pending
Career history
221
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
22.5%
-17.5% vs TC avg
§102
12.2%
-27.8% vs TC avg
§112
34.5%
-5.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 173 resolved cases

Prosecution Timeline

1600
Application Filed
Dec 10, 2025
Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/472,949
Patent 12600798
MEDICINAL COMPOSITION USABLE FOR PREVENTING AND/OR TREATING BLOOD COAGULATION FACTOR IX ABNORMALITY, COMPRISING MULTISPECIFIC ANTIGEN BINDING MOLECULE REPLACING FUNCTION OF BLOOD COAGULATION FACTOR VIII
2y 5m to grant Granted Apr 14, 2026
17/946,941
Patent 12595301
ANTI-IL-2 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
2y 5m to grant Granted Apr 07, 2026
17/639,139
Patent 12583940
MONOCLONAL ANTIBODY WHICH TARGETS TFPI
2y 5m to grant Granted Mar 24, 2026
18/429,244
Patent 12564739
ENGINEERED NATURAL KILLER (NK) CELLS AND COMPOSITIONS AND METHODS THEREOF
2y 5m to grant Granted Mar 03, 2026
17/562,774
Patent 12545745
METHOD FOR TREATING A DEGENERATIVE NEUROLOGICAL DISORDERS COMPRISING ADMINISTERING ASM INHIBITOR
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
92%
With Interview (+27.9%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 173 resolved cases by this examiner. Grant probability derived from career allow rate.

Ready to respond to this office action?

IP Author drafts your complete OA response — amendments, arguments, and claim strategy — in minutes, not days.

Start Drafting Your Response →

Data sourced from USPTO Patent File Wrapper (daily) and Office Action Archive (weekly). Analysis generated by IP Author.

Data: USPTO Patent File Wrapper (daily) • Office Action Archive (weekly) • 89M+ prosecution events

© 2026 IP Author — Browse Office Actions • Examiners • Companies • Firms

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month